Literature DB >> 2979678

Review: first-pass metabolism by the gastrointestinal mucosa.

D J Back1, S M Rogers.   

Abstract

The bioavailability of orally administered drugs may be reduced due to presystemic elimination. The first-pass effect can occur in the gastrointestinal tract, the liver and lung. Although the liver is the main drug metabolizing organ in the body, the gut wall can play an important role in the first-pass metabolism of certain drugs. Both phase I (preconjugation) and phase II (conjugation) reactions have been described. However, while the oxidative metabolic capacity of the intestinal mucosa is considerably smaller than that of the liver, the activity of conjugation reactions in the gut may be close to that of the liver, and in some cases may exceed it. Sulphate conjugation is particularly important for steriod hormones such as ethinyloestradiol, and for the beta-adrenoceptor stimulants isoprenaline and isoetharine. Glucuronidation has been demonstrated to occur in man for morphine, paracetamol and oestrogens. Significant drug--drug interactions have been described involving drugs undergoing sulphate conjugation. The study of intestinal metabolism in vivo is difficult in man since direct methods (for example, hepatic portal vein catheterization) is justified in only a small number of patients. Therefore, much of our present understanding has been derived from various in-vitro studies involving intestinal sheets, mucosal biopsies, isolated enterocytes and microsomal preparations.

Entities:  

Mesh:

Year:  1987        PMID: 2979678     DOI: 10.1111/j.1365-2036.1987.tb00634.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

Review 1.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

2.  Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.

Authors:  Tae Hwan Kim; Soyoung Shin; Cornelia B Landersdorfer; Yong Ha Chi; Soo Heui Paik; Jayhyuk Myung; Rajbharan Yadav; Stefan Horkovics-Kovats; Jürgen B Bulitta; Beom Soo Shin
Journal:  AAPS J       Date:  2015-05-20       Impact factor: 4.009

3.  Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663.

Authors:  M van Heek; C Farley; D S Compton; L Hoos; K B Alton; E J Sybertz; H R Davis
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 4.  Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.

Authors:  M Barry; S Gibbons; D Back; F Mulcahy
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 5.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

6.  The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit.

Authors:  W Homsy; G Caillé; P du Souich
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

Review 7.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

8.  Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa.

Authors:  S Madden; D J Back; C A Martin; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

9.  Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber.

Authors:  A Lampen; U Christians; A K Gonschior; A Bader; I Hackbarth; W von Engelhardt; K F Sewing
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

Review 10.  New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents.

Authors:  Marta Boffito; Akil Jackson; Andrew Owen; Stephen Becker
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.